Biotech entity
Every one of those 1 sits in a single category, clinical-trial. Saccharomyces boulardii CNCM I-745 is most often covered alongside Direct-to-Consumer Microbiome Tests, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Saccharomyces boulardii CNCM I-745, all published on July 28, 2026.
Last mentioned: Jul 28, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. Saccharomyces boulardii CNCM I-745 is most often covered alongside Direct-to-Consumer Microbiome Tests, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Saccharomyces boulardii CNCM I-745, all published on July 28, 2026. Each carries 5 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 5 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Saccharomyces boulardii CNCM I-745. Shared-story counts are live from our verified record — not editorial picks.
The gut microbiome is a rapidly growing focus for biopharma, yet clinical validation remains sparse: only two probiotic strains—Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG—have strong RCT evidence. Without a consensus definition of a healthy microbiome, therapeutic developers face significant regulatory and scientific challenges.
Source: houstonpublicmedia.org · wutc.org
Saccharomyces boulardii CNCM I-745 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
